JP2021522247A - 肝疾患における好中球エラスターゼ阻害薬の使用 - Google Patents

肝疾患における好中球エラスターゼ阻害薬の使用 Download PDF

Info

Publication number
JP2021522247A
JP2021522247A JP2020559442A JP2020559442A JP2021522247A JP 2021522247 A JP2021522247 A JP 2021522247A JP 2020559442 A JP2020559442 A JP 2020559442A JP 2020559442 A JP2020559442 A JP 2020559442A JP 2021522247 A JP2021522247 A JP 2021522247A
Authority
JP
Japan
Prior art keywords
compound
phenyl
liver disease
solvate
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020559442A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021522247A5 (enExample
Inventor
サンジーブ・サティアル
ブライアン・ロバーツ
ワン・シュエヤン
スコット・サベッジ
ホヨン・ホ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
pH Pharma Co Ltd
Original Assignee
pH Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by pH Pharma Co Ltd filed Critical pH Pharma Co Ltd
Publication of JP2021522247A publication Critical patent/JP2021522247A/ja
Publication of JP2021522247A5 publication Critical patent/JP2021522247A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2020559442A 2018-04-24 2019-04-22 肝疾患における好中球エラスターゼ阻害薬の使用 Pending JP2021522247A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862662074P 2018-04-24 2018-04-24
US62/662,074 2018-04-24
PCT/US2019/028551 WO2019209738A1 (en) 2018-04-24 2019-04-22 Use of neutrophil elastase inhibitors in liver disease

Publications (2)

Publication Number Publication Date
JP2021522247A true JP2021522247A (ja) 2021-08-30
JP2021522247A5 JP2021522247A5 (enExample) 2022-04-27

Family

ID=68236763

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020559442A Pending JP2021522247A (ja) 2018-04-24 2019-04-22 肝疾患における好中球エラスターゼ阻害薬の使用

Country Status (11)

Country Link
US (2) US10806735B2 (enExample)
EP (1) EP3784657A4 (enExample)
JP (1) JP2021522247A (enExample)
KR (1) KR20210002573A (enExample)
CN (1) CN113614070A (enExample)
AU (2) AU2019257632A1 (enExample)
CA (1) CA3101274A1 (enExample)
IL (1) IL278207A (enExample)
SG (1) SG11202010521VA (enExample)
TW (1) TW202011965A (enExample)
WO (1) WO2019209738A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN121081472A (zh) 2018-12-13 2025-12-09 拓臻股份有限公司 一种THRβ受体激动剂化合物及其制备方法和用途
CA3154488A1 (en) 2019-08-23 2021-03-04 Terns Pharmaceuticals, Inc. Thyroid hormone receptor beta agonist compounds
CA3154391A1 (en) 2019-09-12 2021-03-18 Terns Pharmaceuticals, Inc. Thyroid hormone receptor beta agonist compounds
US11478533B2 (en) 2020-04-27 2022-10-25 Novo Nordisk A/S Semaglutide for use in medicine
PE20231096A1 (es) 2020-08-25 2023-07-18 Lilly Co Eli Polimorfos de un inhibidor de ssao
EP4210705A4 (en) * 2020-09-11 2024-11-13 Terns Pharmaceuticals, Inc. SOLID DISPERSION FORMULATIONS OF A FXR AGONIST
CN114085173B (zh) * 2021-10-18 2024-04-16 嘉兴学院 一种2-硝基-4-甲砜基苯甲醛的制备方法
CN115976192A (zh) * 2022-12-02 2023-04-18 西安华壹健康医学检验实验室有限公司 一种用ne基因表达量检测评估脂肪肝的方法
CN117357508B (zh) * 2023-11-03 2024-05-17 中山大学孙逸仙纪念医院 西维来司他在制备治疗原发性胆汁性胆管炎的药物中的应用
CN119499379B (zh) * 2024-09-23 2025-09-05 广东医科大学 Elane基因作为心力衰竭靶点的制药用途和西维来司他的新用途

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011506503A (ja) * 2007-12-20 2011-03-03 バイエル・シェーリング・ファルマ・アクチェンゲゼルシャフト ４−（４−シアノ−２−チオアリール）ジヒドロピリミジノンおよびその使用
JP2018501276A (ja) * 2015-01-09 2018-01-18 ギリアド アポロ， エルエルシー 非アルコール性脂肪肝疾患の処置のためのａｃｃ阻害剤併用療法
WO2018064373A1 (en) * 2016-09-28 2018-04-05 Eiger Biopharmaceuticals, Inc. Methods and pharmaceutical compositions for the treatment of non-alcoholic steatohepatitis
JP2018510900A (ja) * 2015-04-07 2018-04-19 インターセプト ファーマシューティカルズ， インコーポレイテッド 併用療法用の医薬組成物

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9475779B2 (en) * 2014-07-31 2016-10-25 Boehringer Ingelheim International Gmbh Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity
AU2015314830B2 (en) * 2014-09-12 2021-01-07 Tobira Therapeutics, Inc. Cenicriviroc combination therapy for the treatment of fibrosis
WO2016050835A2 (en) 2014-10-02 2016-04-07 Ruprecht-Karls-Universität Heidelberg Selective inhibitors of neutrophil elastase for treating neuropathic pain and chronic pain states harbouring a neuropathic component
CA2980071A1 (en) 2015-03-18 2016-09-22 Bayer Pharma Aktiengesellschaft Method for preparation of (4s)-4-[4-cyano-2-(methylsulfonyl)phenyl]-3,6-dimethyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2,3,4-tetrahydro pyrimidine-5-carbonitrile
WO2017081044A1 (en) 2015-11-13 2017-05-18 Bayer Pharma Aktiengesellschaft 4-(4-cyano-2-thioaryl)dihydropyrimidinones for treating chronic wounds
GB201608453D0 (en) 2016-05-13 2016-06-29 Univ Liverpool Muscle regeneration

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011506503A (ja) * 2007-12-20 2011-03-03 バイエル・シェーリング・ファルマ・アクチェンゲゼルシャフト ４−（４−シアノ−２−チオアリール）ジヒドロピリミジノンおよびその使用
JP2018501276A (ja) * 2015-01-09 2018-01-18 ギリアド アポロ， エルエルシー 非アルコール性脂肪肝疾患の処置のためのａｃｃ阻害剤併用療法
JP2018510900A (ja) * 2015-04-07 2018-04-19 インターセプト ファーマシューティカルズ， インコーポレイテッド 併用療法用の医薬組成物
WO2018064373A1 (en) * 2016-09-28 2018-04-05 Eiger Biopharmaceuticals, Inc. Methods and pharmaceutical compositions for the treatment of non-alcoholic steatohepatitis

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
S. ZANG ET AL.: "Neutrophils Play a Crucial Role in the Early Stage of Nonalcoholic Steatohepatitis via Neutrophil El", CELL BIOCHEMISTRY AND BIOPHYSICS, vol. 73(2), JPN7023001229, 2015, pages 479 - 487, ISSN: 0005022102 *
V. AUBERT MANSUY ET AL.: "Imbalance between Neutrophil Elastase and its inhibitor a1-Antitrypsin in Obesity Alters Insulin Sen", CELL METABOLISM, vol. 17, JPN7023001228, 2013, pages 534 - 548, ISSN: 0005022103 *

Also Published As

Publication number Publication date
WO2019209738A1 (en) 2019-10-31
EP3784657A4 (en) 2022-02-09
US10806735B2 (en) 2020-10-20
AU2019257632A1 (en) 2020-11-26
US20210069192A1 (en) 2021-03-11
IL278207A (en) 2020-11-30
KR20210002573A (ko) 2021-01-08
TW202011965A (zh) 2020-04-01
US20190321364A1 (en) 2019-10-24
SG11202010521VA (en) 2020-11-27
EP3784657A1 (en) 2021-03-03
AU2024227697A1 (en) 2024-11-21
CA3101274A1 (en) 2019-10-31
CN113614070A (zh) 2021-11-05

Similar Documents

Publication Publication Date Title
US10806735B2 (en) Use of neutrophil elastase inhibitors in liver disease
CN102091330B (zh) 含有缬沙坦和nep抑制剂的药物组合物
JP6557684B2 (ja) 線維性疾患の治療に用いられるｐｐａｒ化合物
JP7697885B2 (ja) 化合物の製剤およびそれらの使用
KR20170003527A (ko) 경구 투여용 펜토산 폴리설페이트 염의 조성물
CN103735530A (zh) 吡非尼酮与药物可接受的赋型剂的胶囊制剂
CN116528833A (zh) 治疗前列腺癌的方法
HK1210694A1 (en) Improvement of the bioavailability of active substances having an amidine function in medicaments
KR101516677B1 (ko) 지방성 간 질환의 치료용 의약 조성물
CN112469415B (zh) 用于预防或治疗非酒精性脂肪性肝炎的药物组合物
JP2020516622A (ja) ゲムカベン、薬学的に許容されるその塩、その組成物、およびその使用方法
TWI606826B (zh) 艾拉莫德或其鹽之用途
KR20220124739A (ko) 암의 치료를 위한 병용 요법
PT1799199E (pt) Uso de inibidores da renina para a prevenção ou tratamento da disfunção diastólica ou insuficiência cardíaca diastólica
JP2022505033A (ja) ゲムカベン、薬学的に許容されるその塩、その組成物、およびその使用方法
JP2010526849A (ja) 心筋梗塞の治療のための鉄キレート剤の使用
EP2586442A1 (en) Sustained-release therapeutic agent for hypertension and renal dysfunction
KR20210028339A (ko) Hdac 저해제와 항 pd-1 항체 또는 항 pd-l1 항체를 포함하는 약학 조성물
KR20250105460A (ko) Kras 억제제 및 shp2 억제제를 포함하는 조합 요법
Dhareshwar Case study: enalapril: a prodrug of enalaprilat
JP2004175786A (ja) Ｉ型アレルギー疾患治療用組成物
JPS63225381A (ja) 肝疾患治療剤
KR20070084122A (ko) 장폴립 억제제
CN101180053A (zh) 铁在发病机制中发挥作用的肝病的治疗
WO2005117853A1 (ja) 高脂血症治療剤及び糖尿病治療剤

Legal Events

Date Code Title Description
RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20210917

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20210921

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220419

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220419

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20230222

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230328

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230616

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20231130